Scholar Rock Holding (SRRK) Receivables - Other (2022 - 2026)
Scholar Rock Holding's quarterly Receivables - Other came in at $2.8 million in Q1 2026, up 46.35% year-on-year from $1.9 million in Q1 2025, and up 1.64% quarter-over-quarter from $2.8 million in Q4 2025.
Scholar Rock Holding has reported Receivables - Other for 5 years, with the latest figure at $2.8 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Other rose 46.35% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 46.35% YoY), and the FY2025 full-year result was $2.8 million, up 30.13% from the prior year.
- Receivables - Other for Q1 2026 stood at $2.8 million, up from $2.8 million in the prior quarter.
- The five-year high for Receivables - Other was $3.5 million in Q3 2025, with the low at $1.1 million in Q4 2023.
- Average Receivables - Other over 5 years is $2.1 million, with a median of $2.0 million recorded in 2025.
- Year-over-year, Receivables - Other tumbled 60.66% in 2023 and surged 216.88% in 2025.
- Tracing SRRK's Receivables - Other over 5 years: stood at $2.7 million in 2022, then plunged by 60.66% to $1.1 million in 2023, then soared by 99.91% to $2.2 million in 2024, then jumped by 30.13% to $2.8 million in 2025, then increased by 1.64% to $2.8 million in 2026.
- The last three Receivables - Other figures came in at $2.8 million (Q1 2026), $2.8 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.85 Mn |
| Mar 31, 2026 | 2.85 Mn |
| Dec 31, 2025 | 2.80 Mn |
| Dec 31, 2025 | 2.80 Mn |
| Sep 30, 2025 | 3.55 Mn |
| Sep 30, 2025 | 3.55 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 1.94 Mn |
| Mar 31, 2025 | 1.94 Mn |
| Dec 31, 2024 | 2.15 Mn |
| Dec 31, 2024 | 2.15 Mn |
| Sep 30, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 1.08 Mn |
| Dec 31, 2023 | 1.08 Mn |
| Dec 31, 2022 | 2.74 Mn |
| Dec 31, 2022 | 2.74 Mn |